Biological E to make two of Takeda's vaccines for India and China markets

Japanese firm will transfer its measles and acellular pertussis vaccine bulk technology to BE

Japanese global pharmaceutical company Takeda and Hyderabad-based vaccine maker Biological E. Limited(BE) announced on Monday that they have entered into a collaboration under which two licensing agreements to expedite the development and delivery of affordable combination vaccines have been executed.

Under the agreements, Takeda Pharmaceutical Company Limited will conduct a transfer from Japan to BE its existing measles and acellular pertussis vaccine bulk production technology, including the provision of technical services such as support in infrastructure review, training for production and quality control, technical assistance in process development, preclinical study design, and production of clinical batch and also the first